APGE

Apogee Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website apogeetherapeutics.com
Employees(FY) -
ISIN US03770N1019

Performance

-2.57%

+4.21%

-21.07%

+19.76%

+63.96%

YTD

+54.24%

Profile

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of APGE 2024-12-27

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 3 indicating strong bearish pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 28 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of APGE

Stock Rank

Recent News & Updates

2024-12-25 06:33
This Apogee Therapeutics Insider Increased Their Holding In The Last Year(Simply Wall St.)
2024-12-17 06:29
Daily – Vickers Top Buyers & Sellers for 12/17/2024(Argus Research)
2024-12-10 07:00
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions(GlobeNewswire)
2024-12-09 18:00
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions(Globenewswire)
2024-12-03 06:52
Apogee Therapeutics Advances in I&I Disease Treatments(TipRanks)
2024-12-02 07:00
Wedbush Adjusts Price Target on Apogee Therapeutics to $90 From $87, Maintains Outperform Rating(MT Newswires)
2024-12-02 06:00
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day(GlobeNewswire)
2024-12-01 17:00
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day(Globenewswire)
2024-11-29 13:00
Apogee Therapeutics Announces Agenda for Virtual R&D Day(GlobeNewswire)
2024-11-29 00:00
Apogee Therapeutics Announces Agenda for Virtual R&D Day(Globenewswire)
2024-11-25 07:08
Canaccord Genuity Initiates Apogee Therapeutics at Buy With $89 Price Target(MT Newswires)
2024-11-18 07:30
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024(GlobeNewswire)
2024-11-17 18:30
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024(Globenewswire)
2024-11-14 07:22
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans(Simply Wall St.)
2024-11-13 07:21
Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028(TipRanks)
2024-11-12 08:45
Apogee Therapeutics' Q3 Net Loss Widens(MT Newswires)
2024-11-12 07:00
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results(GlobeNewswire)
2024-11-11 18:00
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-11-04 07:30
Apogee Therapeutics to Participate in Upcoming November Investor Conferences(GlobeNewswire)
2024-11-03 18:30
Apogee Therapeutics to Participate in Upcoming November Investor Conferences(Globenewswire)
2024-10-24 08:00
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases(GlobeNewswire)
2024-10-23 20:00
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases(Globenewswire)
2024-10-16 07:00
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting(GlobeNewswire)
2024-10-15 19:00
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting(Globenewswire)
2024-10-07 16:50
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now(Insider Monkey)
2024-10-07 04:50
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now(Insidermonkey)
2024-10-07 03:18
Apogee Therapeutics Insider Sold Shares Worth $2,249,307, According to a Recent SEC Filing(MT Newswires)
2024-10-04 13:03
Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc(GuruFocus.com)
2024-09-12 07:00
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit(GlobeNewswire)
2024-09-11 19:00
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.